Eosinophilic Granulomatosis with Polyangiitis after mRNA-1273 SARS-CoV-2 Vaccine
Abstract
1. Introduction
2. Materials and Methods
3. Case Presentation
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Swissmedic 2019, © Copyright Reports of Suspected Adverse Reactions to COVID-19 Vaccines in Switzerland—Update 23. Available online: https://www.swissmedic.ch/swissmedic/en/home/news/coronavirus-covid-19/covid-19-vaccines-safety-update-13.html (accessed on 25 March 2022).
- Yan, M.Z.; Yang, M.; Lai, C.-L. Review of Clinical Trials of COVID-19 Vaccination Booster in SARS-CoV-2 Variants Era: To Take It or Not to Take It. Front. Drug Discov. 2022, 2, 858006. [Google Scholar] [CrossRef]
- Watad, A.; De Marco, G.; Mahajna, H.; Druyan, A.; Eltity, M.; Hijazi, N.; Haddad, A.; Elias, M.; Zisman, D.; Naffaa, M.E.; et al. Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following MRNA/DNA SARS-CoV-2 Vaccination. Vaccines 2021, 9, 435. [Google Scholar] [CrossRef] [PubMed]
- Carubbi, F.; Alunno, A.; Santilli, J.; Natali, L.; Mancini, B.; Gregorio, N.D.; Pinto, R.D.; Viscido, A.; Grassi, D.; Ferri, C. Immune-Mediated Inflammatory Diseases after Anti-SARS-CoV-2 Vaccines: New Diagnoses and Disease Flares. RMD Open 2022, 8, e002460. [Google Scholar] [CrossRef] [PubMed]
- Chan-Chung, C.; Ong, C.-S.; Chan, L.-L.; Tan, E.-K. Eosinophilic Granulomatosis with Polyangiitis after COVID-19 Vaccination. QJM 2021, 114, 807–809. [Google Scholar] [CrossRef] [PubMed]
- Nappi, E.; De Santis, M.; Paoletti, G.; Pelaia, C.; Terenghi, F.; Pini, D.; Ciccarelli, M.; Selmi, C.F.; Puggioni, F.; Canonica, G.W.; et al. New Onset of Eosinophilic Granulomatosis with Polyangiitis Following MRNA-Based COVID-19 Vaccine. Vaccines 2022, 10, 716. [Google Scholar] [CrossRef]
- Ibrahim, H.; Alkhatib, A.; Meysami, A. Eosinophilic Granulomatosis With Polyangiitis Diagnosed in an Elderly Female After the Second Dose of MRNA Vaccine Against COVID-19. Cureus 2022, 14, e21176. [Google Scholar] [CrossRef]
- Lai, Y.W.; Chua, C.G.; Lim, X.R.; Francis, P.J.; Xu, C.; Howe, H.S. Autoimmune Rheumatic Disease Flares with Myocarditis Following COVID-19 MRNA Vaccination: A Case-Based Review. Vaccines 2022, 10, 1772. [Google Scholar] [CrossRef]
- Hakroush, S.; Tampe, B. Case Report: ANCA-Associated Vasculitis Presenting With Rhabdomyolysis and Pauci-Immune Crescentic Glomerulonephritis After Pfizer-BioNTech COVID-19 MRNA Vaccination. Front. Immunol. 2021, 12, 762006. [Google Scholar] [CrossRef]
- Klok, F.A.; Pai, M.; Huisman, M.V.; Makris, M. Vaccine-Induced Immune Thrombotic Thrombocytopenia. Lancet Haematol. 2022, 9, e73–e80. [Google Scholar] [CrossRef]
- Grayson, P.C.; Ponte, C.; Suppiah, R.; Robson, J.C.; Craven, A.; Judge, A.; Khalid, S.; Hutchings, A.; Luqmani, R.A.; Watts, R.A.; et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis. Ann. Rheum. Dis. 2022, 74, 393–399. [Google Scholar] [CrossRef]
- Chakraborty, R.K.; Aeddula, N.R. Churg Strauss Syndrome. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2021. [Google Scholar]
- Barbind, K.L.; Boddu, R.; Shijith, K.P.; Mishra, K. Hypereosinophilia: A Rare Cause of Stroke and Multiorgan Dysfunction. BMJ Case Rep. 2021, 14, e242619. [Google Scholar] [CrossRef] [PubMed]
- Badiola, J.; Navarrete-Navarrete, N.; Sabio, J.M. Thrombotic Microangiopathy in a Patient with Eosinophilic Granulomatosis with Polyangiitis: Case-Based Review. Rheumatol. Int. 2019, 39, 359–365. [Google Scholar] [CrossRef] [PubMed]
- Olivieri, B.; Betterle, C.; Zanoni, G. Vaccinations and Autoimmune Diseases. Vaccines 2021, 9, 815. [Google Scholar] [CrossRef]
- Scully, M.; Singh, D.; Lown, R.; Poles, A.; Solomon, T.; Levi, M.; Goldblatt, D.; Kotoucek, P.; Thomas, W.; Lester, W. Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 NCoV-19 Vaccination. N. Engl. J. Med. 2021, 384, 2202–2211. [Google Scholar] [CrossRef] [PubMed]
- Pishko, A.M.; Cuker, A. Thrombosis After Vaccination With Messenger RNA-1273: Is This Vaccine-Induced Thrombosis and Thrombocytopenia or Thrombosis With Thrombocytopenia Syndrome? Ann. Intern. Med. 2021, 174, 1468–1469. [Google Scholar] [CrossRef] [PubMed]
- Sangli, S.; Virani, A.; Cheronis, N.; Vannatter, B.; Minich, C.; Noronha, S.; Bhagavatula, R.; Speredelozzi, D.; Sareen, M.; Kaplan, R.B. Thrombosis With Thrombocytopenia After the Messenger RNA-1273 Vaccine. Ann. Intern. Med. 2021, 174, 1480–1482. [Google Scholar] [CrossRef] [PubMed]
- Groh, M.; Pagnoux, C.; Baldini, C.; Bel, E.; Bottero, P.; Cottin, V.; Dalhoff, K.; Dunogué, B.; Gross, W.; Holle, J.; et al. Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force Recommendations for Evaluation and Management. Eur. J. Intern. Med. 2015, 26, 545–553. [Google Scholar] [CrossRef] [PubMed]
- Ghanima, W.; Khelif, A.; Waage, A.; Michel, M.; Tjønnfjord, G.E.; Romdhan, N.B.; Kahrs, J.; Darne, B.; Holme, P.A. RITP study group Rituximab as Second-Line Treatment for Adult Immune Thrombocytopenia (the RITP Trial): A Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial. Lancet 2015, 385, 1653–1661. [Google Scholar] [CrossRef]
- Teixeira, V.; Mohammad, A.J.; Jones, R.B.; Smith, R.; Jayne, D. Efficacy and Safety of Rituximab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis. RMD Open 2019, 5, e000905. [Google Scholar] [CrossRef]
- Pugnet, G.; De Moreuil, C.; Bonnotte, B.; Benhamou, Y.; Diot, E.; Chauveau, D.; Duffau, P.; Limal, N.; Neel, A.; Urbanski, G.; et al. Rituximab versus Conventional Therapeutic Strategy for Remission Induction in Eosinophilic Granulomatosis with Polyangiitis: A Double-blind, Randomized, Controlled Trial. Controlled Trial [abstract]. Arthritis Rheumatol. 2021, 73 (Suppl. 9). Available online: https://acrabstracts.org/abstract/rituximab-versus-conventional-therapeutic-strategy-for-remission-induction-in-eosinophilic-granulomatosis-with-polyangiitis-a-double-blind-randomized-controlled-trial/ (accessed on 3 August 2023).
- Gioffredi, A.; Maritati, F.; Oliva, E.; Buzio, C. Eosinophilic Granulomatosis with Polyangiitis: An Overview. Front. Immunol. 2014, 5, 549. [Google Scholar] [CrossRef]
- Anderson, E.J.; Rouphael, N.G.; Widge, A.T.; Jackson, L.A.; Roberts, P.C.; Makhene, M.; Chappell, J.D.; Denison, M.R.; Stevens, L.J.; Pruijssers, A.J.; et al. Safety and Immunogenicity of SARS-CoV-2 MRNA-1273 Vaccine in Older Adults. N. Engl. J. Med. 2020, 383, 2427–2438. [Google Scholar] [CrossRef] [PubMed]
- Gill, R.; Rizvi, M.; Sadiq, M.S.; Feldman, M. Recrudescence of Severe Polyneuropathy after Receiving Pfizer-BioNTech COVID-19 Vaccine in a Patient with a History of Eosinophilic Granulomatosis with Polyangiitis. BMJ Case Rep. 2022, 15, e245749. [Google Scholar] [CrossRef] [PubMed]
- Costanzo, G.; Ledda, A.G.; Ghisu, A.; Vacca, M.; Firinu, D.; Del Giacco, S. Eosinophilic Granulomatosis with Polyangiitis Relapse after COVID-19 Vaccination: A Case Report. Vaccines 2022, 10, 13. [Google Scholar] [CrossRef]
- Luchetti Gentiloni, M.M.; Paci, V.; Marconi, V.; Gigli, M.; Benfaremo, D.; Sordillo, R.; Macchini, C.; Massaccesi, L.; Perna, G.P.; Offidani, A.M.; et al. SARS-COV-2 Infection, Vaccination, and Immune-Mediated Diseases: Results of a Single-Center Retrospective Study. Front. Immunol. 2022, 13, 859550. [Google Scholar] [CrossRef] [PubMed]
- Lee, A.R.Y.B.; Wong, S.Y.; Tay, S.H. Booster COVID-19 Vaccines for Immune-Mediated Inflammatory Disease Patients: A Systematic Review and Meta-Analysis of Efficacy and Safety. Vaccines 2022, 10, 668. [Google Scholar] [CrossRef]
Case | Age, Gender | Pre-Existing Respiratory Disease | Pre-Existing EGPA (Treatment) | mRNA Vaccine Type | Time between Immunization and EGPA Symptom Onset in Days (Vaccine Dose) | Clinical Presentation | Complications | Peak Blood Eosinophil Count (G/L) | ANCA Positivity (Type) | FFS | Treatment Received |
---|---|---|---|---|---|---|---|---|---|---|---|
[5] | 62, F | Asthma | No | BNT161b2 | Few days (2nd dose) | Fever, numbness in feet and palms, walking disability, purpura, peri-orbital edema | Polyneuropathy, optic nerves inflammation, myocarditis, vasculitis at cutaneous biopsy | 13.4 | Yes (anti-MPO) | 1 | MP, RTX |
[6] | 63, M | Allergic rhino-sinusitis and asthma | No | mRNA-1273 | 1 (1st dose) | Diplopia, headache, dry cough | 3rd cranial nerve palsy, myopericarditis | 12.4 | No | 2 | MP, P, CYC |
[9] | 79, F | No | No | BNT162b2 | 14 (2nd dose) | Myalgia, Weakness | Rhabdomyolysis, acute kidney injury, pauci-immune crescentic glomerulonephritis, and interstitial nephritis with prominent eosinophilia | 5.3 | Yes (p-ANCA, anti-MPO) | 1 | MP, P, CYC |
[7] | 79, F | Asthma | No | mRNA-1273 | 14 (2nd dose) | Progressive paraesthesia of hands and feet, myalgia, walking disability | DVT, vasculitic neuropathy with eosinophil infiltration | 12.4 | Yes (p-ANCA, anti-MPO) | 0 | P, AZA |
[25] | N/A, M | Rhino-sinusitis and asthma | Yes (untreated for 7 years) | BNT162b2 | 5 (1st dose) | Weakness, neuropathic pain, blurry vision | Polyneuropathy, mild left foot drop | 0.94 | No | 0 | P |
[26] | 71, F | Rhino-sinusitis and asthma | Yes (MEP, ICS) | BNT162b2 | 10 (1st dose) | Myalgia, arthralgia, dyspnoea, cough, chest pain, paraesthesia | Mononeuritis multiplex | 4.3 | Yes (p-ANCA) | 0 | MP, P, BEN |
[8] | 63, F | Allergic rhinitis and asthma | Yes (AZA) | mRNA-1273 | 14 (1st dose) | Dyspnoea, chest pain | Myocarditis | 0.88 | No | 1 | MP. P. CYC |
[8] | 64, M | Asthma and rhinosinusitis with nasal polyps | No (but constitutional symptoms for 3 months) | BNT162b2 | 2 (1st dose) | Numbness in thigh, purpura, chest pain | Endomyocarditis, cutaneous vasculitis, mononeuritis multiplex, possible glomerulonephritis | 5.39 | No | 1 | MP, P, CYC |
Present case | 46, F | Allergic rhino-sinusitis and asthma | No | mRNA-1273 | 4 (2nd dose) | Enteritis, fever, fatigue, myalgia | Myocarditis, multiple strokes, immune thrombocytopenia | 8.4 | No | 2 | MP, P, IVIG, RPL, RTX, BEN |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Mencarelli, L.; Moi, L.; Dewarrat, N.; Monti, M.; Alberio, L.; Ringwald, M.; Swierdzewska, K.; Panagiotis, A.; Ribi, C. Eosinophilic Granulomatosis with Polyangiitis after mRNA-1273 SARS-CoV-2 Vaccine. Vaccines 2023, 11, 1335. https://doi.org/10.3390/vaccines11081335
Mencarelli L, Moi L, Dewarrat N, Monti M, Alberio L, Ringwald M, Swierdzewska K, Panagiotis A, Ribi C. Eosinophilic Granulomatosis with Polyangiitis after mRNA-1273 SARS-CoV-2 Vaccine. Vaccines. 2023; 11(8):1335. https://doi.org/10.3390/vaccines11081335
Chicago/Turabian StyleMencarelli, Lucrezia, Laura Moi, Natacha Dewarrat, Matteo Monti, Lorenzo Alberio, Maxime Ringwald, Karolina Swierdzewska, Antiochos Panagiotis, and Camillo Ribi. 2023. "Eosinophilic Granulomatosis with Polyangiitis after mRNA-1273 SARS-CoV-2 Vaccine" Vaccines 11, no. 8: 1335. https://doi.org/10.3390/vaccines11081335
APA StyleMencarelli, L., Moi, L., Dewarrat, N., Monti, M., Alberio, L., Ringwald, M., Swierdzewska, K., Panagiotis, A., & Ribi, C. (2023). Eosinophilic Granulomatosis with Polyangiitis after mRNA-1273 SARS-CoV-2 Vaccine. Vaccines, 11(8), 1335. https://doi.org/10.3390/vaccines11081335